Tamara Timic Stamenic
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcium Channels, T-Type | 9 | 2025 | 96 | 4.840 |
Why?
| | Hypnotics and Sedatives | 5 | 2025 | 199 | 2.220 |
Why?
| | Thalamus | 4 | 2025 | 110 | 2.140 |
Why?
| | Pregnanolone | 3 | 2025 | 37 | 2.030 |
Why?
| | Hypnosis | 2 | 2025 | 11 | 1.910 |
Why?
| | Neurons | 7 | 2025 | 1613 | 1.570 |
Why?
| | Intralaminar Thalamic Nuclei | 2 | 2019 | 16 | 1.210 |
Why?
| | Receptors, GABA-A | 9 | 2016 | 141 | 1.170 |
Why?
| | Isoflurane | 5 | 2025 | 31 | 1.120 |
Why?
| | Pregnanediones | 1 | 2025 | 9 | 0.960 |
Why?
| | Conditioning, Classical | 1 | 2025 | 108 | 0.880 |
Why?
| | Membrane Potentials | 3 | 2022 | 294 | 0.870 |
Why?
| | Maze Learning | 8 | 2016 | 102 | 0.850 |
Why?
| | Anesthetics, General | 1 | 2022 | 8 | 0.760 |
Why?
| | Fear | 1 | 2025 | 354 | 0.740 |
Why?
| | Diazepam | 7 | 2016 | 35 | 0.710 |
Why?
| | Electrophysiological Phenomena | 4 | 2025 | 59 | 0.700 |
Why?
| | Androstanols | 1 | 2020 | 18 | 0.680 |
Why?
| | Nitriles | 1 | 2020 | 175 | 0.640 |
Why?
| | Dizocilpine Maleate | 2 | 2018 | 22 | 0.630 |
Why?
| | Mice, Inbred C57BL | 8 | 2025 | 5792 | 0.620 |
Why?
| | Action Potentials | 3 | 2020 | 502 | 0.600 |
Why?
| | Amphetamine | 3 | 2016 | 34 | 0.570 |
Why?
| | GABA-A Receptor Agonists | 4 | 2016 | 16 | 0.570 |
Why?
| | Ventral Tegmental Area | 1 | 2018 | 58 | 0.550 |
Why?
| | Memory Disorders | 2 | 2015 | 165 | 0.530 |
Why?
| | Anesthesia | 1 | 2019 | 191 | 0.520 |
Why?
| | Mice, Knockout | 7 | 2025 | 3020 | 0.520 |
Why?
| | Animals | 25 | 2025 | 37011 | 0.520 |
Why?
| | Hyperkinesis | 1 | 2015 | 17 | 0.480 |
Why?
| | Reflex, Righting | 2 | 2025 | 15 | 0.480 |
Why?
| | Adenosine Triphosphate | 1 | 2018 | 487 | 0.480 |
Why?
| | Electroencephalography | 4 | 2025 | 438 | 0.470 |
Why?
| | Rats, Wistar | 12 | 2016 | 457 | 0.470 |
Why?
| | Mice | 9 | 2025 | 17843 | 0.430 |
Why?
| | GABA Modulators | 2 | 2012 | 12 | 0.430 |
Why?
| | Midazolam | 1 | 2012 | 56 | 0.390 |
Why?
| | Benzodiazepines | 4 | 2015 | 153 | 0.380 |
Why?
| | Memory | 1 | 2012 | 257 | 0.350 |
Why?
| | Brain | 2 | 2020 | 2831 | 0.330 |
Why?
| | Sex Characteristics | 2 | 2025 | 766 | 0.330 |
Why?
| | Male | 23 | 2025 | 67718 | 0.320 |
Why?
| | Rats | 13 | 2019 | 5676 | 0.300 |
Why?
| | Imidazoles | 2 | 2016 | 244 | 0.260 |
Why?
| | Patch-Clamp Techniques | 2 | 2025 | 288 | 0.260 |
Why?
| | Calcium Channels, R-Type | 1 | 2025 | 5 | 0.230 |
Why?
| | Behavior, Animal | 4 | 2021 | 514 | 0.230 |
Why?
| | Somatosensory Cortex | 1 | 2025 | 39 | 0.230 |
Why?
| | Carbolines | 3 | 2013 | 32 | 0.230 |
Why?
| | Gene Silencing | 1 | 2025 | 195 | 0.220 |
Why?
| | RNA, Small Interfering | 1 | 2025 | 621 | 0.200 |
Why?
| | Anesthetics, Inhalation | 2 | 2021 | 35 | 0.200 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2501 | 0.190 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2014 | 179 | 0.180 |
Why?
| | Motor Activity | 5 | 2018 | 723 | 0.180 |
Why?
| | Calcium Channel Blockers | 2 | 2020 | 168 | 0.170 |
Why?
| | Ventral Thalamic Nuclei | 1 | 2019 | 4 | 0.160 |
Why?
| | Nitrous Oxide | 1 | 2019 | 33 | 0.150 |
Why?
| | Models, Animal | 1 | 2020 | 387 | 0.150 |
Why?
| | Rats, Transgenic | 1 | 2018 | 19 | 0.150 |
Why?
| | Protein Isoforms | 1 | 2019 | 403 | 0.140 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 77 | 0.140 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 101 | 0.140 |
Why?
| | Cytosol | 1 | 2018 | 227 | 0.140 |
Why?
| | Female | 8 | 2025 | 73162 | 0.130 |
Why?
| | Synaptic Transmission | 1 | 2019 | 291 | 0.130 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 394 | 0.130 |
Why?
| | GABA-A Receptor Antagonists | 2 | 2012 | 19 | 0.130 |
Why?
| | Anxiety | 2 | 2014 | 1041 | 0.120 |
Why?
| | Risperidone | 1 | 2015 | 29 | 0.120 |
Why?
| | Emulsions | 1 | 2015 | 54 | 0.120 |
Why?
| | Anti-Anxiety Agents | 2 | 2013 | 46 | 0.120 |
Why?
| | Dopamine | 1 | 2018 | 301 | 0.120 |
Why?
| | Schizophrenia | 2 | 2015 | 446 | 0.110 |
Why?
| | Maternal Exposure | 1 | 2015 | 188 | 0.110 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 222 | 0.100 |
Why?
| | Muscarinic Antagonists | 1 | 2012 | 28 | 0.100 |
Why?
| | Spatial Behavior | 1 | 2012 | 26 | 0.100 |
Why?
| | Muscle Relaxation | 1 | 2012 | 20 | 0.100 |
Why?
| | Ataxia | 1 | 2012 | 45 | 0.100 |
Why?
| | Lipopolysaccharides | 1 | 2015 | 886 | 0.090 |
Why?
| | Drug Stability | 2 | 2016 | 167 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2013 | 2066 | 0.090 |
Why?
| | Xenopus laevis | 2 | 2016 | 104 | 0.090 |
Why?
| | Cognition Disorders | 1 | 2015 | 517 | 0.090 |
Why?
| | Seizures | 1 | 2014 | 431 | 0.080 |
Why?
| | Hand Strength | 2 | 2016 | 122 | 0.080 |
Why?
| | Nanoparticles | 1 | 2015 | 484 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2015 | 608 | 0.080 |
Why?
| | Cognition | 1 | 2015 | 1192 | 0.070 |
Why?
| | Locomotion | 1 | 2016 | 100 | 0.060 |
Why?
| | Epilepsy, Absence | 1 | 2025 | 9 | 0.060 |
Why?
| | HEK293 Cells | 1 | 2016 | 734 | 0.050 |
Why?
| | Calcium Channels, L-Type | 1 | 2025 | 118 | 0.050 |
Why?
| | Kinetics | 1 | 2016 | 1679 | 0.050 |
Why?
| | Flumazenil | 2 | 2012 | 8 | 0.050 |
Why?
| | Adjuvants, Anesthesia | 1 | 2021 | 12 | 0.050 |
Why?
| | Isomerism | 1 | 2021 | 56 | 0.050 |
Why?
| | Ion Transport | 1 | 2020 | 62 | 0.040 |
Why?
| | Benzamides | 1 | 2020 | 218 | 0.040 |
Why?
| | Piperidines | 1 | 2020 | 208 | 0.040 |
Why?
| | Inhibitory Postsynaptic Potentials | 1 | 2019 | 47 | 0.040 |
Why?
| | Excitatory Postsynaptic Potentials | 1 | 2019 | 125 | 0.040 |
Why?
| | Emulsifying Agents | 1 | 2015 | 2 | 0.030 |
Why?
| | Lecithins | 1 | 2015 | 5 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 15 | 0.030 |
Why?
| | Technology, Pharmaceutical | 1 | 2015 | 21 | 0.030 |
Why?
| | Poloxamer | 1 | 2015 | 13 | 0.030 |
Why?
| | Polysorbates | 1 | 2015 | 41 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2015 | 108 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 249 | 0.030 |
Why?
| | Particle Size | 1 | 2015 | 394 | 0.030 |
Why?
| | Humans | 2 | 2022 | 137514 | 0.030 |
Why?
| | Drug Inverse Agonism | 1 | 2012 | 3 | 0.030 |
Why?
| | Protein Subunits | 1 | 2014 | 238 | 0.030 |
Why?
| | Autistic Disorder | 1 | 2015 | 203 | 0.030 |
Why?
| | Rotarod Performance Test | 1 | 2012 | 16 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 2012 | 17 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 363 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2012 | 105 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2015 | 778 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2013 | 218 | 0.020 |
Why?
| | Reaction Time | 1 | 2012 | 432 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2015 | 1242 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2015 | 640 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2074 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 315 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 508 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4295 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 6745 | 0.010 |
Why?
|
|
Timic Stamenic's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|